Diagnostic Test for H pylori

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

TUSTIN, Ca--AMDL, Inc. has filed a 510(k) Premarket Notification with the FDA for PyloriProbe, its diagnostic test for the detection of Heli-cobacter pylori. This bacterium is associated with chronic gastritis and gastric and duodenal ulcers, and has been classified by WHO as a class I carcinogen that increases the risk of developing stomach cancer. Pylori-Probe is a direct enzyme immunoassay (EIA) that detects the presence of H pylori antibodies in serum samples.

TUSTIN, Ca--AMDL, Inc. has filed a 510(k) Premarket Notificationwith the FDA for PyloriProbe, its diagnostic test for the detectionof Heli-cobacter pylori. This bacterium is associated withchronic gastritis and gastric and duodenal ulcers, and has beenclassified by WHO as a class I carcinogen that increases the riskof developing stomach cancer. Pylori-Probe is a direct enzymeimmunoassay (EIA) that detects the presence of H pyloriantibodies in serum samples.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
2 experts are featured in this series.
Related Content